alexa Membranous nephropathy | Singapore| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences
  • Global Physicians and Healthcare Congress
    June 25-27, 2018 Dubai, UAE
  • International Conference on Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • 11th International Conference on Clinical and Medical Case Reports
    October 22-23, 2018 Istanbul, Turkey

Relevant Topics

Membranous Nephropathy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Membranous nephropathy

    Membranous nephropathy is a kidney disorder that leads to changes and inflammation of the structures inside the kidney that help filter wastes and fluids. The inflammation may lead to problems with kidney function.

  • Membranous nephropathy

    Disease pathophysiology: 

    Autoantibodies to PLA2R, usually of IgG4 subclass, are found in 70-80% of patients with primary membranous nephropathy, bind to conformational epitopes on PLA2R expressed in the glomerular podocyte, form immune complexes in situ and induce proteinuria, mostly likely via local activation of complement. The autoimmune response is governed by genes at the HLA-DQA1 locus. 

  • Membranous nephropathy

    Disease statistics:

    The epidemiologic information concerning chronic renal failure (CRF) in children is scanty, particularly with regard to the less advanced stages of renal impairment that are potentially more susceptible to therapeutic interventions aimed at changing the course of the disease and avoiding end-stage renal disease (ESRD). 

  • Membranous nephropathy

    Disease treatment:

    The treatment consisted of 1g intravenous methylprednisolone given every 24 hours for three consecutive days, followed by oral steroids at a dose of 0.5 mg/kg/daily for 27 days (Cycle A). After the first month steroid treatment was replaced by chlorambucil (0.2 mg/kg/daily) for one month (Cycle B). Cycle A and B were repeated three times, so that the whole treatment lasted 6 months.

  • Membranous nephropathy

    Major research on disease: 

    To understand the mechanisms whereby proteinuria is prevented in the healthy situation, with a focus on the two highly  specialised cell types that make up the filtration barrier in the glomerulus; the glomerular epithelial cell or podocyte and the glomerular endothelial cell (GEnC) that lines the glomerular capillary wall, how they communicate with eachother and how this may change in  disease.

Expert PPTs

Speaker PPTs

  • Hayam I Gad
    Effects of Pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of Diabetic nephropathy in an experimental model of diabetic renal disease
    PPT Version | PDF Version

High Impact List of Articles

Conference Proceedings